JP2016510030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510030A5 JP2016510030A5 JP2015560330A JP2015560330A JP2016510030A5 JP 2016510030 A5 JP2016510030 A5 JP 2016510030A5 JP 2015560330 A JP2015560330 A JP 2015560330A JP 2015560330 A JP2015560330 A JP 2015560330A JP 2016510030 A5 JP2016510030 A5 JP 2016510030A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- powder
- salt
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 73
- 150000001875 compounds Chemical class 0.000 claims description 53
- 239000000843 powder Substances 0.000 claims description 53
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 230000001225 therapeutic effect Effects 0.000 claims description 25
- 239000004615 ingredient Substances 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 15
- 229940126530 T cell activator Drugs 0.000 claims description 12
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 9
- 229940022399 cancer vaccine Drugs 0.000 claims description 9
- 238000009566 cancer vaccine Methods 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 8
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- -1 phosphorothioate diester Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 150000004713 phosphodiesters Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- MFEFTTYGMZOIKO-UHFFFAOYSA-N 5-azacytosine Chemical group NC1=NC=NC(=O)N1 MFEFTTYGMZOIKO-UHFFFAOYSA-N 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 229940116741 CD137 agonist Drugs 0.000 claims description 2
- 229940123189 CD40 agonist Drugs 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 2
- 125000005587 carbonate group Chemical group 0.000 claims description 2
- 150000005690 diesters Chemical class 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 125000004437 phosphorous atom Chemical group 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229950007217 tremelimumab Drugs 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000009098 adjuvant therapy Methods 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 208000005890 Neuroma Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108060006580 PRAME Proteins 0.000 description 2
- 102000036673 PRAME Human genes 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- ZADWXFSZEAPBJS-JTQLQIEISA-N 1-methyl-L-tryptophan Chemical compound C1=CC=C2N(C)C=C(C[C@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-JTQLQIEISA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 C*[C@@](C1*)O[C@](C*)C1O*OC[C@@]1O[C@@](*)C(*)C1O* Chemical compound C*[C@@](C1*)O[C@](C*)C1O*OC[C@@]1O[C@@](*)C(*)C1O* 0.000 description 1
- RIGXDDLTUVREEK-QWVXHKJYSA-N C=NC(NC1=O)=Nc2c1nc[n]2[C@@H](C1)O[C@H](CO)C1OP(OC[C@H](C(C1)O)O[C@H]1N(C=NC(N)=N1)C1=O)(S)=O Chemical compound C=NC(NC1=O)=Nc2c1nc[n]2[C@@H](C1)O[C@H](CO)C1OP(OC[C@H](C(C1)O)O[C@H]1N(C=NC(N)=N1)C1=O)(S)=O RIGXDDLTUVREEK-QWVXHKJYSA-N 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 101000972276 Homo sapiens Mucin-5B Proteins 0.000 description 1
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 102100022494 Mucin-5B Human genes 0.000 description 1
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 description 1
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- FBSLIOLWUSOMBA-LVNZIBFLSA-N NC(NC1=O)=Nc2c1nc[n]2[C@@H](C1)OC(COP(OC(C2)[C@@H](CO)O[C@H]2N(C=NC(N)=N2)C2=O)(S)=O)=C1O Chemical compound NC(NC1=O)=Nc2c1nc[n]2[C@@H](C1)OC(COP(OC(C2)[C@@H](CO)O[C@H]2N(C=NC(N)=N2)C2=O)(S)=O)=C1O FBSLIOLWUSOMBA-LVNZIBFLSA-N 0.000 description 1
- KZGMYLPSSQZSLO-GECHRPJISA-N NC(NC1=O)=Nc2c1nc[n]2[C@@H](C1OC(c2ccccc2)=O)O[C@H](CO)C1OP(O)(OC[C@H](C(C1OC(c2ccccc2)=O)O)O[C@H]1N(C=NC(N)=N1)C1=O)=O Chemical compound NC(NC1=O)=Nc2c1nc[n]2[C@@H](C1OC(c2ccccc2)=O)O[C@H](CO)C1OP(O)(OC[C@H](C(C1OC(c2ccccc2)=O)O)O[C@H]1N(C=NC(N)=N1)C1=O)=O KZGMYLPSSQZSLO-GECHRPJISA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100027009 Toll-like receptor 10 Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 102100039490 X antigen family member 1 Human genes 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 208000022806 beta-thalassemia major Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 208000010485 smooth muscle tumor Diseases 0.000 description 1
- XLHBNJPXFOZFNJ-BYKQGDNKSA-M sodium;[(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] phosphate Chemical compound [Na+].O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP([O-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 XLHBNJPXFOZFNJ-BYKQGDNKSA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771525P | 2013-03-01 | 2013-03-01 | |
| US61/771,525 | 2013-03-01 | ||
| US201361887165P | 2013-10-04 | 2013-10-04 | |
| US61/887,165 | 2013-10-04 | ||
| PCT/US2014/019137 WO2014134355A1 (en) | 2013-03-01 | 2014-02-27 | Drug combinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019076111A Division JP2019142911A (ja) | 2013-03-01 | 2019-04-12 | 薬物組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510030A JP2016510030A (ja) | 2016-04-04 |
| JP2016510030A5 true JP2016510030A5 (https=) | 2017-03-30 |
| JP6514647B2 JP6514647B2 (ja) | 2019-05-15 |
Family
ID=50288308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560330A Expired - Fee Related JP6514647B2 (ja) | 2013-03-01 | 2014-02-27 | 薬物組み合わせ |
| JP2019076111A Pending JP2019142911A (ja) | 2013-03-01 | 2019-04-12 | 薬物組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019076111A Pending JP2019142911A (ja) | 2013-03-01 | 2019-04-12 | 薬物組み合わせ |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160015805A1 (https=) |
| EP (2) | EP3563836A1 (https=) |
| JP (2) | JP6514647B2 (https=) |
| KR (1) | KR20150125963A (https=) |
| CN (2) | CN105025884B (https=) |
| AU (1) | AU2014223348B2 (https=) |
| CA (1) | CA2902433A1 (https=) |
| CY (1) | CY1122554T1 (https=) |
| DK (1) | DK2961388T3 (https=) |
| ES (1) | ES2734023T3 (https=) |
| HR (1) | HRP20191171T1 (https=) |
| HU (1) | HUE044430T2 (https=) |
| IL (2) | IL240894B (https=) |
| LT (1) | LT2961388T (https=) |
| MX (2) | MX366967B (https=) |
| PH (2) | PH12015501905A1 (https=) |
| PL (1) | PL2961388T3 (https=) |
| PT (1) | PT2961388T (https=) |
| RU (2) | RU2019138702A (https=) |
| SA (1) | SA515360959B1 (https=) |
| SG (2) | SG10201707135RA (https=) |
| SI (1) | SI2961388T1 (https=) |
| WO (1) | WO2014134355A1 (https=) |
| ZA (2) | ZA201506150B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| EP3431142B1 (en) | 2011-08-30 | 2020-06-17 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CA2942245C (en) | 2014-03-12 | 2021-11-02 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| PL3142751T3 (pl) | 2014-05-13 | 2019-12-31 | Medimmune Limited | Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca |
| JP6626085B2 (ja) * | 2014-07-15 | 2019-12-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法 |
| EP3925968A3 (en) | 2014-10-07 | 2022-03-02 | Cytlimic Inc. | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell |
| WO2016061231A1 (en) * | 2014-10-14 | 2016-04-21 | Deciphera Pharmaceuticals, Llc | Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression |
| US10525035B2 (en) | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| CN113388021A (zh) | 2015-03-09 | 2021-09-14 | Cytlimic公司 | 源于gpc3的肽、使用其的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法 |
| RU2709015C2 (ru) * | 2015-04-07 | 2019-12-13 | Ситлимик Инк. | Лекарственное средство |
| AU2016287585B2 (en) * | 2015-07-02 | 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
| GB201704966D0 (en) * | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| RU2020108580A (ru) | 2017-08-03 | 2021-09-03 | Оцука Фармасьютикал Ко., Лтд. | Лекарственное соединение и способы его очистки |
| US20210002371A1 (en) * | 2017-12-21 | 2021-01-07 | Brian A. Sherer | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| CN108948203B (zh) * | 2018-08-09 | 2019-06-04 | 南京鼓楼医院 | 抗pd-1单克隆抗体及其制备方法和应用 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| JP7460094B2 (ja) * | 2020-04-24 | 2024-04-02 | ジェネクシン・インコーポレイテッド | 子宮頸がんの治療方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| CZ298364B6 (cs) | 1998-02-05 | 2007-09-05 | Smithkline Beecham Biologicals S. A. | Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| PT1187629E (pt) * | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US20030148973A1 (en) | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
| WO2003103389A2 (en) * | 2002-06-10 | 2003-12-18 | Avax Technologies Inc. | Cryopreservation of haptenized tumor cells |
| WO2005033278A2 (en) | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| US20050266012A1 (en) * | 2004-05-26 | 2005-12-01 | Jean-Marie Andrieu | Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same |
| WO2006048749A1 (en) | 2004-11-04 | 2006-05-11 | Pfizer Products Inc. | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
| PL1833506T3 (pl) | 2004-12-29 | 2016-01-29 | Mannkind Corp | Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych |
| AU2006204896A1 (en) * | 2005-01-14 | 2006-07-20 | Avax Technologies, Inc. | Method for producing a vaccine for the treatment of cancer |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| PL1928492T3 (pl) * | 2005-09-01 | 2011-09-30 | Celgene Corp | Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| RU2612521C2 (ru) * | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| PT2769737T (pt) * | 2009-07-20 | 2017-06-29 | Bristol Myers Squibb Co | Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas |
| AU2010305284A1 (en) * | 2009-10-06 | 2012-05-03 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| GB201006096D0 (en) * | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| MX349622B (es) | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| NZ713461A (en) * | 2011-04-15 | 2017-02-24 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| EP3431142B1 (en) * | 2011-08-30 | 2020-06-17 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| EP2958571B1 (en) * | 2013-02-21 | 2024-04-10 | Michele Maio | Dna hypomethylating agents for cancer therapy |
-
2014
- 2014-02-27 CA CA2902433A patent/CA2902433A1/en not_active Abandoned
- 2014-02-27 SG SG10201707135RA patent/SG10201707135RA/en unknown
- 2014-02-27 US US14/771,011 patent/US20160015805A1/en not_active Abandoned
- 2014-02-27 MX MX2015011147A patent/MX366967B/es active IP Right Grant
- 2014-02-27 PT PT14710728T patent/PT2961388T/pt unknown
- 2014-02-27 EP EP19163282.7A patent/EP3563836A1/en not_active Withdrawn
- 2014-02-27 CN CN201480011754.5A patent/CN105025884B/zh not_active Expired - Fee Related
- 2014-02-27 LT LTEP14710728.8T patent/LT2961388T/lt unknown
- 2014-02-27 WO PCT/US2014/019137 patent/WO2014134355A1/en not_active Ceased
- 2014-02-27 CN CN201910760009.5A patent/CN110448566A/zh active Pending
- 2014-02-27 SI SI201431263T patent/SI2961388T1/sl unknown
- 2014-02-27 HU HUE14710728 patent/HUE044430T2/hu unknown
- 2014-02-27 RU RU2019138702A patent/RU2019138702A/ru unknown
- 2014-02-27 EP EP14710728.8A patent/EP2961388B1/en active Active
- 2014-02-27 SG SG11201506727RA patent/SG11201506727RA/en unknown
- 2014-02-27 ES ES14710728T patent/ES2734023T3/es active Active
- 2014-02-27 JP JP2015560330A patent/JP6514647B2/ja not_active Expired - Fee Related
- 2014-02-27 PL PL14710728T patent/PL2961388T3/pl unknown
- 2014-02-27 DK DK14710728.8T patent/DK2961388T3/da active
- 2014-02-27 RU RU2015141628A patent/RU2708246C2/ru active
- 2014-02-27 KR KR1020157025503A patent/KR20150125963A/ko not_active Ceased
- 2014-02-27 AU AU2014223348A patent/AU2014223348B2/en not_active Ceased
- 2014-02-27 HR HRP20191171TT patent/HRP20191171T1/hr unknown
-
2015
- 2015-08-24 ZA ZA201506150A patent/ZA201506150B/en unknown
- 2015-08-27 IL IL240894A patent/IL240894B/en active IP Right Grant
- 2015-08-27 MX MX2019008822A patent/MX2019008822A/es unknown
- 2015-08-28 PH PH12015501905A patent/PH12015501905A1/en unknown
- 2015-08-30 SA SA515360959A patent/SA515360959B1/ar unknown
-
2019
- 2019-04-12 JP JP2019076111A patent/JP2019142911A/ja active Pending
- 2019-07-10 CY CY20191100738T patent/CY1122554T1/el unknown
- 2019-07-17 US US16/514,377 patent/US20200009247A1/en not_active Abandoned
- 2019-08-16 ZA ZA2019/05426A patent/ZA201905426B/en unknown
- 2019-10-17 PH PH12019550222A patent/PH12019550222A1/en unknown
-
2020
- 2020-09-15 IL IL277385A patent/IL277385A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510030A5 (https=) | ||
| JP6514647B2 (ja) | 薬物組み合わせ | |
| US12226480B2 (en) | Combination drug including TLR7 agonist | |
| JP2021503450A (ja) | プログラム可能なポリマー薬 | |
| JP2021506788A (ja) | 生物学的に活性な化合物を含むイオン性ポリマー | |
| JP2021510696A (ja) | 生物学的に活性な化合物を含む剛性間隔基を有するポリマー | |
| JP2021510700A (ja) | 生物学的に活性な化合物を含むホスホアルキルポリマー | |
| JP2023159392A (ja) | 癌の治療のための免疫原性組成物 | |
| JP2019530671A5 (https=) | ||
| JP2022533020A (ja) | がん免疫療法アジュバント | |
| JP7023968B2 (ja) | 骨がんまたは血液がんの治療のための治療薬としてのホスファプラチン化合物 | |
| KR20210068060A (ko) | 주사용 조성물 | |
| JP2020533305A (ja) | 免疫調節剤としてのホスファプラチン化合物およびその治療的使用 | |
| CN110891944A (zh) | 用于治疗癌症的化合物、组合物及其用途 | |
| Arabi | Development of a MUC1 Cancer Immunotherapy Using Complement Targeted Liposomes and Organoplatinum (IV) Complex as an Effective Anticancer Drug | |
| KR20160086960A (ko) | 암 치료를 위한 화합물 및 방법 | |
| HK40034217A (en) | Combination drug including tlr7 agonist | |
| NZ750690B2 (en) | Drug combinations comprising derivatives of decitabine | |
| NZ711757B2 (en) | Drug combinations comprising derivatives of decitabine | |
| BR112017001974B1 (pt) | Combinação, uso da mesma e kit para o tratamento de tumores | |
| BG112633A (bg) | Антинеопластичен състав |